On another note, with all these new institutional holders, I wouldn't be surprised to see Zami & his lackey Yaky get the boot at the next shareholder meeting. That would probably be the best thing for this company.
Hey cal. I'm here, but unfortunately there hasn't been much to say. The only tangible positive has been the increase in institutional holdings. Otherwise, the company continues to release fluff while we await the completion of the IC trial. On the ARS front, we're looking pretty good but again it's a waiting game for the initiation of the PH1 human safety trial for PLX-R18.
To me, it seems the company is having a hard time moving forward. For whatever reasons, they still have not started any new trials despite all the hype they created, especially on the CLI front. I also question why there isn't any progress with the orthopedic indications.
It's been frustrating but hopefully things will pan out. Meanwhile, I'm just waiting it out like many others here.